Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

ients maintain a higher ribavirin

dose. However, physicians could only prescribe EPO after the first dose

ribavirin reduction in the "IDEAL" trial. Since patients in the Peg-

Intron arms generally had smaller ribavirin dose reductions, this

introduces another potential bias and means those Peg-Intron patients

were potentially able to maintain a higher dose of ribavirin compared

to PEGASYS patients

About PEGASYS

PEGASYS was launched by Roche in 2002 and quickly became the leading treatment for patients with hepatitis C. It is indicated in combination with COPEGUS (ribavirin) for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA- approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treatment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and pa
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board ... Officer announced that Tamas Feitel has joined ... joins Numotion after a highly successful 18 year career ... roles driving strategy, profitability, and productivity to result in ... recent position was Chief Financial Officer for GE Healthcare ...
(Date:7/2/2015)... , July 2, 2015 ... (Homofermentative & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes ... and Forecast to 2020", Silage Inoculants & Enzymes Market ... a CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ...
(Date:7/2/2015)... de 2015 BGI anunció hoy que su ... rendimiento en Hong Kong ha ... instalación de BGI en Hong Kong ... generación que recibe la certificación CAP en ... prácticas de laboratorio clínico. Junto con el exitoso proceso ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI recibe la acreditación del College of American Pathologists (CAP) 2
... Inc. (Nasdaq: MSHL ), an oncology company ... cancer metabolism, announced today that it has filed a ... Exchange Commission for a rights offering to existing stockholders ... stock. The Company will announce further details regarding the ...
... Feb. 21, 2012  Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... will present a company overview at Citi,s 2012 Global Health ... ET at the Waldorf Astoria in New York City. ... available on the "Investors & Media" section of the Company,s ...
Cached Medicine Technology:Marshall Edwards Announces Rights Offering to Stockholders 2Marshall Edwards Announces Rights Offering to Stockholders 3
(Date:7/3/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... truth and expose popular lies regarding proper relationships according to the bible. ... into the core of the subject by explaining why certain types of sexual relationships ...
(Date:7/2/2015)... ... 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... Lone Star State. The premium frozen yogurt chain was listed as #22 on the Inc. ... in the Village at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... retrofit project at the University of Minnesota, they knew it would save the ... also be an award-winning choice: the total energy savings after installation was an ...
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured on NewsWatch ... products available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, ... versatile smart light bulbs on the market. , According to the U.S. Department of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Six months ahead of his 80th birthday, ... raise awareness and money for the Pulmonary Hypertension Association (PHA). Stevenson began the ... near Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday morning and is making ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3
... in an attempt to find out how various eating ... the blood pressures of meat eaters, fish eaters, vegetarians, ... Health Nutrition, showed how healthy eating habits could help ... in the comparative study - some with high blood ...
... on birth control pills have been linking them to ... pills. However, a new study published by Walter Spitzer, ... contradicted previous studies by stating that women who take ... no increased risk for heart attack compared to women ...
... observed a pill-sized camera and a CT scan may prove ... small intestine. The newly approved camera capsule, also known as ... before available. A patient swallows the pill and, for eight ... on the person's abdomen.// The pictures can then be viewed ...
... have discovered that it might be possible for tear-free GM ... the chemical in onions that makes you cry is not ... of Tokyo and Kyoto University,//tested the theory that the crying ... Alliinase plays a part in the chemical reactions that give ...
... that cloned animals tend to harbor genetic defects that ... the rational that reproductive cloning of humans should be ... be used safely for therapeutic cloning techniques, such as ... Parkinson's to diabetes. Cloned animals have major ...
... shown in a new study, that soy can lower cholesterol ... studies give more reason to dish up the soy protein ... fatty acids, which are found in abundance in fish, //flax ... health benefits. But researchers suggest they also produce physiological effects ...
Cached Medicine News:Health News:Cut meat to cut blood pressure 2Health News:No heart attack risk for women taking birth control pills 2Health News:Genetic failure in cloned animals 2Health News:Soy, Omega 3s convalesce artery health 2Health News:Soy, Omega 3s convalesce artery health 3
... Powerful and Flexible Impact And Impact2 Pipettors ... volume ranges, our single channel Impact and ... of any application. Engineered with the same ... multichannel line, these pipettors are equally easy ...
... The total ergonomic solution and best ... Soft, feather touch action and ultra ... strain, Stress-free tip ejection with long, ... easy volume identification, Accepts universal tips ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Inquire...
Medicine Products: